21.08.2012 - Sanofi withdraws a cancer drug from the markets and aims for a relaunch in multiple sclerosis.
Sanofi is withdrawing its cancer drug Campath from the markets. The pharma plans to commercialise the antibody under a different name and dosing regime for multiple sclerosis – a much more lucrative indication.
The development of Campath-1H, also known under its generic name alemtuzumab, as a successful drug took years. The anti-CD52 antibody was thought to cure rheumatoid arthritis in the beginning of the 90s but failed expectations. Since 2001, it has finally been approved for chronic lymphocytic leukaemia (CLL). Since then it also washes some money into Sanofi’s subsidiary Genzyme Corp. from Cambridge (USA). But revenues have been decling over the past years. Therefore Sanofi is now aiming for fresh money and a higher pricing. In a move to prevent off-label use the drug has now been pulled from European (in mid-August) and US markets (in early September) markets.
In both regions the market authorisation applications (MAAs) for a use in multiple sclerosis are pending. According to the pharma company clearing the market should ensure that „alemtuzumab is exclusively received and used in the ongoing clinical trials.“ Obviously, Sanofi thinks that a widely merchandised drug could jeopardise these trials. Alemtuzumab awaits its repeated market entry under the name Lemtrada. However, the German society for haematology and oncology (DGHO) criticises Sanofi for playing one group of patients against another. Sanofi responded that all leukaemia patients (so far about 4.000) will benefit from free-of-charge programmes that make sure that all patients receive their much needed medicine. In Germany, according to the DGHO, these programmes run so far quite smoothly even if they mean an increased bureaucratic effort.
26.08.2016 Adocia said it would discontinue its diabetic foot ulcer programme after its lead product BioChaperone PDGF disappointed in Phase III. The French company will turn the focus on its earlier-stage products.
24.08.2016 Pharma major Pfizer is putting the cherry on top of its multi-billion-dollar takeover of Medivation with the acquisition of AstraZeneca’s antibiotics for a cool US$1.5bn. With the divestment, AZ aims to further sharpen its focus.
23.08.2016 Cambridge University-allied investor Cambridge Innovation Capital has raised £75m (€87m) to reinvest in technology and healthcare companies. Among the backers were Woodford Investment and Winton Ventures.
19.08.2016 Together with partner Johnson & Johnson, Danish biotech Genmab is now one step closer to FDA approval with its combination treatment for multiple myeloma after its submission of a supplemental Biologics License Application. In July, Genmab was granted a Breakthrough Therapy Designation (BTD) for its blood cancer therapy.
17.08.2016 Philip Hammond, the UK’S chancellor has announced the government will guarantee funding for EU-backed "structural and investment fund" projects whose timelines extend beyond the UK’s departure from the EU, provided the projects are signed prior to this year's Autumn Statement on the UK budget. The decision ensures continued funding for farmers, companies and institutions involved in the EU’s Horizon 2020 project. The move could cost the UK government up to £6bn (€6.9bn).
15.08.2016 Back in April, the American FDA gave the green light for the colorectal cancer-screening test Epi procolon. Now Berlin-based diagnostics specialist Epigenomics is considering a secondary listing in the US. A draft of the required registration document was confidentially submitted to the US Securities and Exchange Commission (SEC).
09.08.2016 Hungarian Gedeon Richter and Irish Allergan are staying on course in the face of dissappointing Phase III results for depression drug cariprazine. The partners will now begin another Phase III study needed for approval.
08.08.2016 Araclon Biotech’s Alzheimer’s vaccine ABvac40 is going forward into Phase II after showing a good safety profile in Phase I. The promising trial results were presented at the Alzheimer’s Association International Conference.
FILTRODISC™ BIO SD is a filtration system which removes particles (e.g. cells, bacteria, yeast), impurities (e.g. HCP, DNA) and other turbid matter from process liquids (e.g. fermentation broths). more